Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial

• Published in: Journal of the European Academy of Dermatology and Venereology 2011-05, Vol.25 (5), p.559-564
• Main Authors: Prinz, JC, FitzGerald, O, Boggs, RL, Foehl, J, Robertson, D, Pedersen, R, Molta, CT, Freundlich, B
• Format: Article
• Language: English
• Subjects: Adult; Age; anti-tumour necrosis factor; Antirheumatic Agents - therapeutic use; Arthritis; Arthritis, Psoriatic - drug therapy; Arthritis, Psoriatic - physiopathology; dactylitis; Dermatologic Agents - therapeutic use; Double-Blind Method; Drug Administration Schedule; enthesitis; Etanercept; Female; Humans; Immunoglobulin G - therapeutic use; Joint diseases; Male; Middle Aged; Psoriasis; Psoriasis - drug therapy; Psoriasis - physiopathology; psoriatic arthritis; Quality of Life; Receptors, Tumor Necrosis Factor - therapeutic use; Severity of Illness Index; Skin; Treatment Outcome
• ISSN: 0926-9959; 1468-3083
• DOI: 10.1111/j.1468-3083.2010.03838.x

Background  Psoriasis and psoriatic arthritis (PsA) affect skin, and/or joints and quality of life (QoL). Objective  To better assess the success in multiple attributes in subjects with both active psoriasis and PsA, the objective was to quantify the proportion of those who achieved substantial improvement in a composite measure of skin symptoms, joint manifestations, and QoL, on one of two treatment regimens. Methods  Subjects (n = 752) with psoriasis and PsA (mean age: 46.5 years, 62.9% male) received etanercept (ETN) 50 mg twice weekly (BIW; n = 379) or 50 mg weekly (QW; n = 373) for 12 weeks, followed by open‐label ETN 50 mg QW for 12 weeks. Skin and joint symptoms and QoL were assessed using psoriasis area and severity index (PASI), American College of Rheumatology criteria (ACR) and Euro‐QoL (EQ‐5D), respectively. Results  By week 24, 30.6% and 25.8% of subjects receiving ETN 50 mg BIW/QW and ETN 50 mg QW/QW, respectively (P = 0.198) achieved the composite measure of efficacy for skin plus joints plus QoL (PASI 75 + ACR 50 + EQ‐5D VAS >82). Conclusion  At 24 weeks, 25.8–30.6% met the triad of rigorous efficacy outcomes. Evaluation of treatment efficacy should address the multiple components of this disease complex; therefore it may be important to consider this composite measure in future trials.